ERBB2 and breast cancer: CAAs decrease the trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) effect in HER2+ BC patients by decreasing the interferon γ secreted by NKs and modifying the tumor cell phenotype via the upregulation of some survival genes, such as DUSP5, MCL1 and CEBPD [149].